我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
37
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
2
5.4%
已完成
27
73.0%
尚未招募
1
2.7%
招募中
3
8.1%
终止
4
10.8%
暂无批准数据
- AbbVie unveiled compelling clinical data at ASH 2025 showcasing advances across multiple blood cancer therapeutic modalities including T-cell engagers, BCL-2 inhibitors, and antibody-drug conjugates. - The phase 3 EPCORE FL-1 trial demonstrated that epcoritamab plus rituximab and lenalidomide reduced disease progression risk by 79% in relapsed/refractory follicular lymphoma patients. - Investigational therapies etentamig and PVEK showed promising efficacy with 81% overall response rates in multiple myeloma and 63.3% complete response rates in acute myeloid leukemia, respectively.
